Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (10)

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2015

  1. Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis

    Oncologist, Vol. 20, Núm. 2, pp. 111-112

2014

  1. Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk

    European Journal of Cancer, Vol. 50, Núm. 18, pp. 3168-3177

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

  2. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population

    BMC Cancer, Vol. 13

  3. rs12512631 on the Group Specific Complement (Vitamin D-Binding Protein GC) Implicated in Melanoma Susceptibility

    PLoS ONE, Vol. 8, Núm. 3

2012

  1. Role of glutathione S-transferases in melanoma susceptibility: Association with GSTP1 rs1695 polymorphism

    British Journal of Dermatology, Vol. 166, Núm. 6, pp. 1176-1183

2011

  1. A customized pigmentation snp array identifies a novel snp associated with melanoma predisposition in the slc45a2 gene

    PLoS ONE, Vol. 6, Núm. 4

  2. Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility

    European Journal of Cancer, Vol. 47, Núm. 17, pp. 2618-2625